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SUMMARY 
 
Background: There is little evidence about the long-term donor site outcome of latissimus 
dorsi breast reconstruction and no patient-reported outcome measures designed 
specifically for the procedure. 
Methods: A prospective cohort of breast cancer patients having latissimus dorsi 
reconstruction after a mastectomy were recruited from 270 hospitals in the United 
Kingdom. An 18-month follow up questionnaire containing two novel scales was sent to 
consenting patients. The prevalence of aesthetic and functional morbidity at the donor site 
was described. The two new scales were refined using the Rasch measurement model and 
subsequently validated. 
Results: 1,096 women completed the new scales. 78% of patients reported that no back 
appearance issues had bothered them “most of the time” or “all of the time” in the past 
two weeks. The equivalent figure for functional morbidity was 60%. Four items were 
eliminated following initial psychometric testing. This produced an 8-item Back Appearance 
scale and an 11-item Back and Shoulder Function scale. Both scales showed adequate fit to 
the Rasch measurement model. Higher levels of aesthetic and functional bother were 
observed for completely autologous procedures versus those where latissimus dorsi 
reconstruction was used to cover an implant (p < 0.05).  Higher levels of aesthetic bother 
were observed in women who had suffered a perioperative complication at the donor site 
(p = 0.003). 
Conclusion: These results can inform patients of the morbidity associated with latissimus 
dorsi reconstruction. The new scales can be used to compare groups undergoing different 
variations of the procedure and to monitor individual patients. 
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Introduction 
Latissimus dorsi (LD) breast reconstruction involves rotating a flap of muscle, skin, fat and 
blood vessels from the upper back to the mastectomy site. There are two main types of LD 
reconstruction. The first involves the use of LD tissue to cover an implant. The second 
involves a pedicled flap of completely autologous tissue and is commonly known as an 
extended LD reconstruction. The largest study of LD reconstruction to date remains the UK 
National Mastectomy and Breast Reconstruction Audit, which recruited patients in 2008 and 
2009. This found that both types of LD reconstruction were associated with higher patient-
reported breast appearance scores than implant-only procedures, but slightly worse breast 
appearance scores than reconstruction with abdominal tissue.1 Morbidity at the donor site 
must also be considered when comparing different types of breast reconstruction. The LD 
muscle can be functionally impaired when it is used in a breast reconstruction, pulling the 
arm back into the body, and turning it inward. There may also be aesthetic damage to the 
back which can be exacerbated by wound infection and skin necrosis. Two systematic 
reviews, both published in 2014, have synthesised the available literature on functional 
outcomes.3,4 The reviews, which were limited by a reliance on small, single-centre studies, 
found that LD procedures lead to measurable reductions in shoulder and upper back 
strength and function in the short term. There was insufficient evidence to provide clear 
guidance on the extent of functional morbidity beyond six months. There is little published 
literature on aesthetic outcomes at the LD donor site. This may be due to an untested 
assumption that women are unconcerned by the appearance of their back because it is 
rarely visible to them. For both functional and aesthetic outcomes there are no patient-
reported outcome measures that have been developed specifically for LD patients. It is 
possible, therefore, that the measures used in previous studies have lacked content validity. 
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In this study, we describe the long-term donor site morbidity arising from LD breast 
reconstruction after mastectomy in a large prospective cohort study using the STROBE 
(Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. The 
psychometric properties of two new measurement scales developed specifically for LD 
reconstruction patients are also described. 
 
Methods 
The data presented in this paper are from the National Mastectomy and Breast 
Reconstruction Audit, which recruited patients between 1 January 2008 and 31 March 2009 
from 270 public and private hospitals in the United Kingdom.5 Data on surgical procedures 
and patient characteristics were prospectively recorded for women aged 16 years and over 
with a diagnosis of invasive carcinoma of the breast, or ductal carcinoma in-situ, undergoing 
mastectomy with immediate reconstruction or primary delayed reconstruction following a 
previous mastectomy. Written consent to participate in a follow-up survey was also 
obtained. 
 
Questionnaires were sent to the home address of consenting patients 18 months after 
surgery and included two new scales designed to evaluate the aesthetic and functional 
outcomes of LD flap reconstruction. The scales are part of the BREAST-Q family of patient-
reported outcome measures.6,7 They were developed in qualitative work with patients who 
had undergone LD flap reconstruction in the United States, and pre-tested with English 
breast cancer patients to ensure acceptability. The resulting Back Appearance (9 items) and 
Back and Shoulder Function scales (14 items) asked patients to record how often in the past 
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two weeks they had been bothered by a set of problems, using five response options: none 
of the time, a little of the time, some of the time, most of the time and all of the time. 
Endorsement frequencies were used to quantify the morbidity of an LD procedure. 
 
The new scales were tested using two distinct measurement paradigms. The dominant 
paradigm in quality of life measurement has traditionally been Classical Test Theory (CTT).8,9 
In CTT, observed patient responses are considered equal to a theoretical true score plus 
random error. The observed score on a scale is assumed to be a random variable which 
produces a bell-shaped curve around the true score. The error score is taken to have a value 
of zero as positive and negative errors cancel each other. A major difficulty with CTT is the 
need to measure repeatedly in order to reduce the size of random errors around individual 
patient scores. In practice, CTT is rarely used to measure individual patients, and error is 
dealt with by focusing on groups of patients only. CTT also does not evaluate the extent to 
which scales have interval level properties and this may lead to inappropriate usage when 
scores are analysed.  Although limited, CTT provides a useful measure of the group-level 
reliability of a scale through a statistic known as ‘Cronbach’s alpha’.10 This produces a 
coefficient which varies between 0 and 1 where higher values indicate higher levels of 
internal consistency among scale items and, by extension, higher levels of reliability. A 
second CTT analysis was performed to assess whether the items in each scale measure a 
common underlying construct. This was evaluated by examining the correlation between 
each item and scale score computed from the remaining items in that scale. Corrected item-
total correlation ≥ 0.30 were taken as sufficient to satisfy this criterion.11 
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In a second stage of scale development, RUMM2030 software was used to test the extent to 
which patient responses fit the Rasch measurement model.12 The Rasch model can be used 
to develop scales with invariant, interval level measurement properties. The answers to 
individual questions in a health outcome measure are usually summed to produce a total 
score, but to do this one must have measurement invariance. This requires that the relative 
location of any two persons on a scale is independent of the items used and conversely the 
relative location of any two items on the continuum is independent of the person on which 
they are measured.13 If a scale is invariant one can treat the interval between, for example, 
scores of 50 and 60 on a 100 point scale, as equivalent to any other 10 point interval on the 
scale when performing a statistical test. This greatly increases the range of analyses that can 
be used with the data and allows for the precise measurement of individual patients. This is 
a major advantage over most existing measures which can only be used at the group level. 
 
Scale development and testing 
Scale development and testing was carried out in three stages. In stage one, instances 
where item responses were inter-dependent were identified, as this violates the 
requirement of item invariance. Inter-item residual correlations greater than 0.4 were 
considered for elimination, and qualitative considerations such as wording or causal 
relationship were used to select which item in the correlated pair should be eliminated. 
 
In stage two, the extent to which each scale covered the continuum of severity and 
discriminated between different levels of severity was assessed. Person-item threshold 
distributions and item ‘locations’ were used to examine the extent to which each scale was 
properly aligned with patient burden. Location is measured on the logit scale and lower 
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scores represent items that are more likely to be associated with a poorer outcome. A 
further test, known as the Person Separation Index, evaluated the extent to which the scales 
reliably discriminated between patients with different outcomes. A minimum value of 0.7 is 
recommended. 
 
In stage three, items on each scale were examined for adherence to the Rasch model. The 
model posits that the probability of a person responding in a certain way to an item in a 
health outcome scale is a logistic function of the difference between that person’s health 
status and the item’s severity.14 First, the standardised residuals for each item were 
calculated to estimate the extent to which the observed variance deviated from the Rasch 
measurement model. Fit residual values between +/−2.5 demonstrate adequate fit. A 
separate Chi-Square test assessed whether responses to each item were invariant across the 
continuum of difficulty. The p-value for the test was Bonferroni adjusted, and reduced 
sample sizes of 500 were used to avoid the risk of overdetecting misfit. Item characteristic 
curves were examined to determine the severity of misfit when both of these tests were 
failed. Second, the hierarchical order of response options was examined to ensure that it 
was in accordance with the underlying latent variable in question. This test compares the 
difficulty threshold in logits for each response option. Third, the extent to which patients 
undergoing immediate reconstruction answered items differently to patients undergoing 
delayed reconstruction was estimated. This test was performed because of a concern that 
delayed reconstruction patients might, because of their prolonged adjustment to the 
aesthetic and functional impact of a mastectomy, answer questions about LD morbidity 
differently to patients undergoing an immediate reconstruction. This problem, known as 
differential item functioning, was evaluated with an analysis of variance of the standardised 
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response residuals for each item between surgical groups. A Bonferroni adjusted p-value 
was again used to determine statistical significance. 
 
Validation 
We posited that a properly constructed scale of LD morbidity would find higher levels of 
impairment in patients undergoing a completely autologous procedure versus those who 
were receiving LD reconstruction to cover an implant. This is because the autologous 
procedure is more invasive with respect to harvesting material around the LD muscle. We 
also posited that women who had suffered a perioperative complication at the LD donor site 
would have worse outcomes than women who had not. Clinicians recorded all donor site 
complications requiring some form of treatment during the hospital admission. These 
comprised wound infection requiring intravenous antibiotics or surgical debridement, 
wound dehiscence requiring re-closure, skin flap necrosis requiring surgical debridement, 
and haematoma or seroma at the donor site requiring aspiration or drainage. To perform 
these analyses the overall score on each measure for each patient was transformed from a 
logit scale to a 0-100 scale, where higher scores represent a better outcome. The outcomes 
of different groups were then compared using linear multiple regression models, adjusting 
for baseline differences in prognostic variables (age, fitness for surgery15 and ethnicity) that 
were significantly associated with scale scores at the 0.05 significance level. When 
performing these comparisons we defined the minimum clinically important difference as 
0.5 of a standard deviation.16 
 
At the time of the study national cancer audits were exempt from obtaining approval from 
the National Research Ethics Service. Approval to prospectively collect patient identifiable 
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data for analysis and reporting was obtained from the Patient Information Advisory Group 
under Section 60 of the Health and Social Care Act 2001. 
 
Results 
3,389 patients underwent a mastectomy with immediate reconstruction and 1,731 
underwent a delayed reconstruction. 1,579 (47%) of the immediate reconstruction patients 
and 790 (46%) of the delayed reconstruction patients had a LD procedure. 1,551 of the 
women in this combined group were invited to take part in the follow-up survey. The 
remaining women were not invited, largely because of problems with the consent process 
in some hospitals. 1,383 (89%) of the invited women consented to follow-up and 1,109 
(80%) of these women returned a questionnaire at 18 months after their surgery. 13 
patients did not complete the new scales leaving a final sample of 1,096. Patient 
characteristics are shown in Table 1. 
 
The median patient age was 52 years (inter-quartile range = 14 years). 69% underwent an 
immediate reconstruction. Risk factors known to be associated with poor surgical outcomes 
were restricted to a minority of patients. 72% had the highest level of fitness for surgery, 
89% were non-smokers and 83% had a body mass index less than 30. Slightly less than half 
the sample (46%) had their LD reconstruction to cover an implant. 76 of the 1,096 women 
who completed an 18-month questionnaire (6.9%) suffered a donor site complication. 
Reassuringly, this was similar to the proportion seen in the 2,369 patients who were eligible 
for participation in the study (8.7%). This is one indication that the sub-group who 
completed a follow-up questionnaire are generally representative of the larger group of 
eligible patients. 
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Aesthetic morbidity was rare (Table 2). 32% of the sample reported that they had not been 
bothered by any back appearance issues at any time in the past two weeks. 78% reported 
that none of the nine items in the scale bothered them most or all of the time. The most 
commonly reported problems related to clothing restrictions: either having to wear certain 
clothes to hide a back scar (12%) or not being able to wear certain clothes (14%).  
 
Back and shoulder morbidity was slightly more frequent (Table 3) and only 8% of patients 
reported that they had had no functional bother on any item at any time in the past 2 
weeks. However, severe morbidity was confined to a minority and 60% reported that none 
of the 14 items in the scale were bothersome most or all of the time. The items where 
patients most frequently experienced bother most, or all of the time, were carrying heavy 
objects (23%), lifting heavy objects (22%) and reaching for objects (21%). 
 
Psychometric analysis of the Back Appearance scale 
The 9-item version of the Back Appearance showed good internal consistency (Cronbach’s 
alpha coefficient = 0.95) and all items had a high correlation with corrected total scores 
(range = 0.74 to 0.86). A residual correlation of 0.63 was observed between item 8 (‘Wear 
certain clothes to hide back scar’) and item 9 (‘Not being able to wear certain clothes’). We 
eliminated item 9 because the wording used a double negative (being bothered by not being 
able to do something), which might confuse some patients. The 8-item version of the Back 
Appearance scale also had high internal consistency (Cronbach’s alpha coefficient = 0.95) 
and all items continued to be highly associated with the underlying construct (corrected 
item-total correlation range = 0.75 to 0.86). 
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Figure 1 shows the person-item threshold distribution for the 8-item version of the Back 
Appearance Scale. The histogram above the x-axis represents the distribution of patients 
and bars to the right of the scale represent patients with lower levels of aesthetic morbidity. 
The histogram below the x-axis represents the severity of items, and bars to the left of the 
scale represent clinical problems that are more severe. The green curved line is the 
information plot and can be interpreted as the point where the measure has the most 
power to discriminate between patients with different levels of aesthetic morbidity. Figure 1 
shows that the scale as a whole, and individual items, are well aligned with the burden 
reported by patients with at least some aesthetic bother from their surgery, but provide less 
coverage of patients with very mild, or no bother.  
 
Table 4 shows the individual item locations for the 8-item Back Appearance scale. Item 5 
(‘Location of your back scar’) is the most severe item on the scale and item 8 (‘Wear certain 
clothes to hide back scar’) is the least severe. This implies that patients with the worst 
aesthetic outcomes are likely to report experiencing the full range of issues covered by the 
scale, up to and including the location of their back scar. Conversely, patients with the best 
overall outcomes are only likely to be bothered by the need to choose certain clothes, or to 
report no problems at all. The Person Separation Index was acceptable (0.80). 
 
Six items had variance that did not demonstrate ideal fit with the Rasch model but none 
performed inconsistently across ten class intervals of difficulty (Bonferroni adjusted 
significance threshold = 0.00125). There were no instances of threshold disordering or 
differential item functioning. 
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The mean total score on the new Back Appearance scale was 76.7 (SD = 22.0). This implies a 
minimum clinically important difference of 11 points. Patients undergoing a completely 
autologous LD procedure (mean = 75.3) had significantly (adjusted mean difference = -3.4; 
95% CI, -6.0 to -0.7; p = 0.01) worse scores on the Back Appearance scale than those 
undergoing the procedure to cover an implant (mean = 78.4). There was a much larger 
(adjusted mean difference = -8.2; 95% CI, -13.5 to -2.9; p = 0.003) difference between 
women who had suffered a donor site complication (mean = 68.6) and those who had not 
(mean = 77.3), again in the hypothesised direction. In both instances these differences were 
less than our predefined minimum clinically important threshold. 
 
Psychometric analysis of the Back and Shoulder Function scale 
The 14-item version of the Back and Shoulder Function scale had good internal consistency 
(Cronbach’s alpha coefficient = 0.95) and all items were highly correlated with the 
underlying construct (corrected item-total correlation range = 0.65 to 0.82). 
 
High residual correlations between items 1 and 3 (‘Back pain’ and ‘An aching feeling in your 
back area’, r = 0.59), items 2 and 4 (‘Shoulder pain’ and ‘An aching feeling in your shoulder 
area’, r = 0.69) and items 9 and 10 (‘Difficulty lifting heavy objects’ and ‘Difficulty carrying 
heavy objects’, r = 0.85) on the Back and Shoulder Function scale indicated a violation of the 
assumption of invariance that could be removed by eliminating one item from each pair. 
Items 3 and 4, which referred to ‘an aching feeling’ were eliminated as it was felt that items 
1 and 2, which referred to ‘pain’ alone, were clearer for patients. Item 9 (lifting) was also 
eliminated as it was considered to be prior in the causal pathway to carrying heavy objects 
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and therefore did not measure the ultimate functional goal. The 11-item version of the Back 
and Shoulder Function scale also had high internal consistency (Cronbach’s alpha coefficient 
= 0.94) and all items continued to be highly associated with the underlying construct 
(corrected item-total correlation range = 0.61 to 0.83). 
The 11-item Back and Shoulder Function scale was well targeted at patients who reported 
average or high levels of functional morbidity but poorly targeted at those with few or no 
functional problems (Figure 2). Item 5 (‘Shoulder stiffness’) is the most severe item on the 
scale and item 10 (‘Difficulty carrying heavy objects’) is the least severe (Table 5). 
 
The Person Separation Index was acceptable (0.86). Eleven of the 14 items had variance that 
did not fit with the expectations of the Rasch model but only one of these (item 9) 
performed inconsistently across 10 class intervals of difficulty (Chi-square = 28.53; p = 
0.00078; Bonferroni adjusted significance threshold = 0.00091). Inspection of the item 
characteristic curve for this item showed little evidence of a misfit between observed and 
expected scores across different levels of difficulty (Figure 3). There were no instances of 
threshold disordering or differential item functioning. 
 
The mean total score on the new Back and Shoulder Function scale was 66.3 (SD = 18.3). 
This implies a minimum clinically important difference of 9.15 points. Patients undergoing a 
completely autologous procedure (mean = 63.3) had significantly (adjusted mean difference 
= -2.4; 95% CI, -4.6 to -0.2; p = 0.04) worse scores on the Back and Shoulder Function scale 
than those undergoing the procedure to cover an implant (mean = 67.4). This difference was 
not clinically significant according to our predefined threshold for a minimally important 
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difference. No difference was observed between patients who had suffered a complication 
and those who had not (p = 0.37). 
 
Discussion 
This large national prospective cohort study provides detailed outcome data for 1,096 
women undergoing LD reconstruction after mastectomy in 2008 and 2009. The proportion 
of women who received immediate LD reconstruction in our study is high compared to 
current practice. A recent analysis of UK practice found that the popularity of immediate LD 
reconstruction peaked in 2008 and 2009 and has steadily declined since, possibly because of 
improvements in both implant-only and autologous abdominal techniques.17 
 
Two new measures of outcome after LD flap reconstruction were tested for various 
psychometric properties and met most of the criteria assessed. In our judgement, both the 
8-item Back Appearance scale and the 11-item Back and Shoulder Function scale provide 
enough reliable and valid information about different levels of morbidity to allow for the 
calculation of summary scores and use at the individual patient level. 
 
Severe aesthetic bother at the LD donor site was rare at 18 months after surgery. Severe 
functional morbidity was slightly more common but still confined to a minority of patients. 
This indicates that the short-term functional impairments previously reported 3,4 may 
diminish over time, but do not completely resolve for some patients. Patients undergoing 
completely autologous LD procedures had slightly more morbidity on both scales than the 
less invasive classical procedure. These differences were statistically, but not clinically 
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significant. These results provide evidence of the validity of the new scales but also indicate 
that any differences between the two surgical approaches to LD reconstruction are small.  
 
The Back Appearance scale demonstrated that donor site complications have long lasting 
aesthetic consequences for the minority of women affected. This is an important finding and 
is consistent with other research on the impact of surgical complications.18 However, it 
should be noted that the difference was not clinically significant according to our predefined 
threshold. The Back and Shoulder Function scale did not detect a similar effect which may 
be because the complications recorded were largely concerned with damage to the skin 
surface. 
 
This is the largest study of its kind to date and reflects the experiences of women treated in 
a wide range of hospital settings in both the immediate and delayed reconstruction context. 
Outcomes were measured at 18 months after surgery, allowing patients to completely 
recover from the procedure. The outcome scales used in the study were developed with and 
for patients undergoing LD surgery and have been tested using modern psychometric 
methods. Both scales have high levels of completion. The main weakness of the study is the 
failure to recruit a large proportion of eligible patients. This reflects the logistical problems 
associated with the administration of patient-reported outcome measures in more than 270 
treatment settings simultaneously. However, there is no evidence that the recruited 
patients differ significantly from those who were not invited to participate.5 
 
Clinicians can now communicate the frequency of a range of problems associated with LD 
breast reconstruction surgery to prospective patients and be confident that this information 
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is generalizable and covers the full period of recovery. The findings are reassuring: donor 
site morbidity following LD reconstruction is limited and similar to that seen with alternative 
reconstructive options such as a TRAM flap transfer.19 The two scales presented in this 
paper are available on a licensed basis from Memorial Sloan Kettering Cancer Center 
(www.breast-q.org). 
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Figure legends 
Figure 1: Person-item threshold distribution for the 8-item version of the Back Appearance 
scale. 
Figure 2: Person-item threshold distribution for the 11-item Back and Shoulder Function 
scale. 
Figure 3: Item characteristic curve for item 9 of the Back and Shoulder Function scale. 
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Table 1: Patient characteristics (N = 1,096). 
Patient characteristic N %  
Age (years) 18-50  507 46.3 
 >50 589 53.7 
BMI 30+ No 874 82.6 
 Yes 184 17.4 
 Not known 38  
Smoker No 954 89.0 
 Yes 118 11.0 
 Not known 24  
ASA grade I 770 71.6 
 II 293 27.3 
 III/IV 12 1.1 
 Not known 21  
Contralateral surgery No 964 88.0 
 Yes 132 12.0 
Tumour grade DCIS low grade 27 2.6 
 DCIS intermediate grade 54 5.2 
 DCIS high grade 186 17.9 
 Well differentiated/invasive 82 7.9 
25 
 
 Moderately differentiated/invasive 380 36.6 
 Poorly differentiated/invasive 310 29.8 
 Not known 57  
Procedure IR Pedicle with implant 325 29.7 
 IR Autologous pedicle 426 38.9 
 DR Pedicle with implant 180 16.4 
 DR Autologous pedicle 165 15.1 
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Table 2: Endorsement frequencies and missing data levels: 9-item version of the Back Appearance Scale. 
Item Number choosing each option (% of those who gave a response) Number (%) of 
patients who did 
not give a response 
None of 
the time  
A little of 
the time 
Some of 
the time 
Most of 
the time 
All of the 
time 
1. How your back looks 568 (52.7) 243 (22.6) 153 (14.2) 75 (7.0) 38 (3.5) 19 (1.7) 
2. The shape (contour) of your back 612 (56.9) 213 (19.8) 141 (13.1) 66 (6.1) 44 (4.1) 20 (1.8) 
3. The sides of your back not matching 619 (57.8) 207 (19.3) 139 (13.0) 68 (6.4) 37 (3.5) 26 (2.4) 
4. How your back scar looks 535 (50.4) 279 (26.3) 129 (12.2) 71 (6.7) 48 (4.5) 34 (3.1) 
5. The location of your back scar 729 (68.6) 169 (15.9) 91 (8.6) 44 (4.1) 30 (2.8) 33 (3.0) 
6. The length of your back scar 699 (65.6) 198 (18.6) 80 (7.5) 57 (5.4) 31 (2.9) 31 (2.8) 
7. How noticeable your back scar is to others 613 (57.7) 250 (23.5) 110 (10.4) 48 (4.5) 42 (3.9) 33 (3.0) 
8. Wear certain clothes to hide back scar 606 56.5) 216 (20.2) 115 (10.7) 70 (6.5) 64 (6.0) 26 (2.4) 
9. Not being able to wear certain clothes  574 (53.7) 211 (19.8) 129 (12.1) 63 (5.9) 91 (8.5) 28 (2.6) 
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Table 3: Endorsement frequencies and missing data levels: 14-item version of the Back and Shoulder Function Scale. 
Item Number choosing each option (% of those who gave a response) Number (%) of 
patients who did 
not give a response 
None of 
the time  
A little of 
the time 
Some of 
the time 
Most of 
the time 
All of the 
time 
1. Back pain 528 (48.9) 227 (21.0) 207 (19.2) 82 (7.6) 36 (3.3) 16 (1.5) 
2. Shoulder pain 626 (58.0) 224 (20.8) 150 (13.9) 56 (5.2) 23 (2.1) 17 (1.6) 
3. An aching feeling in your back area 457 (42.4) 263 (24.4) 225 (20.9) 93 (8.6) 39 (3.6) 19 (1.7) 
4. An aching feeling in your shoulder area 609 (56.4) 241 (22.3) 141 (13.1) 65 (6.0) 23 (2.1) 17 (1.6) 
5. Shoulder stiffness 665 (61.3) 231 (21.3) 110 (10.1) 56 (5.2) 23 (2.1) 11 (1.0) 
6. Tightness when you stretch your arm 412 (37.8) 302 (27.7) 174 (16.0) 124 (11.4) 77 (7.1) 7 (0.6) 
7. A pulling feeling in your back 392 (36.1) 275 (25.3) 209 (19.3) 129 (11.9) 80 (7.4) 11 (1.0) 
8. Weakness in your arm 482 (44.3) 277 (25.4) 160 (14.7) 100 (9.2) 70 (6.4) 7 (0.6) 
9. Difficulty lifting heavy objects 404 (37.1) 261 (24.0) 188 (17.3) 127 (11.7) 108 (9.9) 8 (0.7) 
10. Difficulty carrying heavy objects 393 (36.1) 257 (23.6) 191 (17.5) 133 (12.2) 115 (10.6) 7 (0.6) 
29 
 
11. Difficulty reaching for objects 382 (35.0) 285 (26.1) 197 (18.1) 124 (11.4) 102 (9.4) 6 (0.5) 
12. Difficulty doing activities, arms outstretched 542 (49.7) 227 (20.8) 166 (15.2) 87 (8.0) 68 (6.2) 6 (0.5) 
13. Difficulty doing activities, arms above head 520 (47.7) 266 (24.4) 157 (14.4) 87 (8.0) 60 (5.5) 6 (0.5) 
14. Difficulty, repeat use of shoulder/back muscles 446 (41.3) 273 (25.2) 171 (15.8) 113 (10.5) 78 (7.2) 15 (1.4) 
Table 4: Item fit statistics for the 8-item version of the Back Appearance scale, ordered by item location. 
Item Location Standard error Fit residual Chi-square Probability 
5. The location of your back scar -0.56 0.05 -3.10 21.83 0.005 
6. The length of your back scar -0.43 0.05 -3.22 15.12 0.057 
7. How noticeable your back scar is to others -0.04 0.05 1.11 13.14 0.107 
3. The sides of your back not matching 0.05 0.05 2.58 12.32 0.137 
1. How your back looks 0.12 0.05 -3.34 17.33 0.027 
2. The shape (contour) of your back 0.15 0.05 1.27 8.55 0.382 
4. How your back scar looks 0.30 0.05 -4.78 20.81 0.008 
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8. Wear certain clothes to hide back scar 0.39 0.05 6.07 25.14 <0.001 
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Table 5: Item fit statistics for the 11-item version of the Back and Shoulder Function scale, ordered by item location. 
Item Location Standard error Fit residual Chi-square Probability 
3. Shoulder stiffness -0.76 0.04 0.72 1.95 0.992 
2. Shoulder pain -0.64 0.04 2.00 9.76 0.371 
1. Back pain -0.20 0.04 5.41 26.98 <0.001 
10. Difficulty doing activities, arms above head -0.10 0.04 -4.90 18.68 0.028 
9. Difficulty doing activities, arms outstretched -0.07 0.04 -6.56 28.53 <0.001 
6. Weakness in your arm 0.05 0.04 -2.91 10.23 0.332 
11. Difficulty, repeat use of shoulder/back muscles 0.18 0.04 -5.06 17.74 0.038 
4. Tightness when you stretch your arm 0.25 0.04 1.62 10.41 0.318 
5. A pulling feeling in your back 0.34 0.04 5.66 22.80 0.007 
8. Difficulty reaching for objects 0.45 0.04 -4.68 18.50 0.030 
7. Difficulty carrying heavy objects 0.51 0.04 -2.78 11.00 0.276 
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